Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215962 | 0.82 | IDO1 (0.47) | IDO1PREPCYP19A1MAPT | |
| SCHEMBL27817497 | 0.81 | IDO1 (0.46) | IDO1PREPCYP19A1MAPTMTNR1A | |
| SCHEMBL7296734 | 0.80 | PREP (0.43) | IDO1PREPCYP19A1MAPTMTNR1A | |
| SCHEMBL30931385 | 0.80 | PREP (0.43) | IDO1PREPCYP19A1MAPTMTNR1A | |
| SCHEMBL28483979 | 0.78 | PREP (0.44) | IDO1PREPCYP19A1MAPTMTNR1A | |
| SCHEMBL7220703 | 0.76 | MAPT (0.46) | IDO1PREPMAPTMTNR1AMTNR1B | |
| SCHEMBL8291564 | 0.76 | IDO1 (0.49) | IDO1PREPCYP19A1MAPTMTNR1A | |
| SCHEMBL16093787 | 0.75 | ALDH1A1 (0.33) | MAPT | |
| SCHEMBL10531104 | 0.74 | NOTUM (0.48) | IDO1 | |
| SCHEMBL1338863 | 0.73 | IDO1 (0.53) | IDO1CYP19A1MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695955-B1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1695955-A1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | LPAR2, LPAR1, LPAR5 | IDO1 356/4885PREP 1135/4885CYP19A1 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.